ExpreS2ion will participate in the 41st annual J.P. Morgan Healthcare Conference and present at Biotech Showcase
Hørsholm, Denmark, January 3, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce that it will present at the Biotech Showcase and will participate in the J.P. Morgan Healthcare Conference from January 9 to 12, 2023.
“This is the first year ExpreS2ion will participate in the annual J.P. Morgan Healthcare Conference and the associated Biotech Showcase. We are looking forward to introducing ExpreS2ion’s pipeline and platform to a new global audience, obtaining inspiration from the world’s leading healthcare companies, and expanding our network at the world’s largest annual healthcare investment symposium,” says CEO Bent Frandsen.
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company’s website.
The J.P. Morgan Healthcare Conference is being held 9-12 January at The Westin St. Francis in San Francisco, California, USA. Both CEO Bent Frandsen and CFO Keith Alexander will participate and take meetings with potential partners and investors. Please contact your J.P. Morgan representative for information about how to attend the event.
The Biotech Showcase is being held 9-11 January at the Hilton San Francisco Union Square, also in San Francisco, California, USA. CEO Bent Frandsen will present the Company at 9:30 am PST on Wednesday January 11th, 2023, at the event. Registration is possible via the Biotech Showcase website.
Parties interested in taking a meeting with either Mr. Frandsen or Mr. Alexander at or around the event should reach out to CFO Keith Alexander directly via the contact details below.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.